<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20020712163159Z</creation_date><modification_date>D:20060321214308+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_w_anx_5.pdf</pdf_file></head><body><section><header n="1">1</header></section><section><header>annex iii  labelling and package leaflet</header><p>2</p></section><section><header>a. labelling</header><p>3</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 50 micrograms powder and solvent for solution for injection – 1 pen, 1 injection
 needle and 2 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 50 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide50 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>1 pen, 1 injection needle and 2 cleansing swabs50 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).4</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/031</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>5</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 50 micrograms powder and solvent for solution for injection – 4 pens, 4 injection
 needles and 8 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 50 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide50 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>4 pens, 4 injection needles and 8 cleansing swabs50 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).6</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/032</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>7</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 50 micrograms powder and solvent for solution for injection – 6 pens, 6 injection
 needles and 12 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 50 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide50 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>6 pens, 6 injection needles and 12 cleansing swabs50 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).8</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/033</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>9</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 50 micrograms powder and solvent for solution for injection – 12 pens, 12 injection
 needles and 24 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 50 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide50 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>12 pens, 12 injection needles and 24 cleansing swabs50 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).10</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/034</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>11</p></section><section><header>minimum particulars to appear on small immediate packaging unitspegintron 50 micrograms powder and solvent for solution for injection
 1.
 name of the medicinal product and route(s) of administration</header><p>pegintron 50 micrograms powder and solvent for injections.c.</p></section><section><header>2.method of administration</header><p>read the package leaflet before use.</p></section><section><header>3.expiry date</header><p>exp</p></section><section><header>4.batch number</header><p>lot</p></section><section><header>5.contents by weight, by volume or by unit</header><p>50 micrograms/0.5 ml12</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 80 micrograms powder and solvent for solution for injection – 1 pen, 1 injection
 needle and 2 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 80 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide80 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>1 pen, 1 injection needle and 2 cleansing swabs80 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).13</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/035</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>14</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 80 micrograms powder and solvent for solution for injection – 4 pens, 4 injection
 needles and 8 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 80 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide80 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>4 pens, 4 injection needles and 8 cleansing swabs80 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).15</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/036</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>16</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 80 micrograms powder and solvent for solution for injection – 6 pens, 6 injection
 needles and 12 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 80 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide80 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>6 pens, 6 injection needles and 12 cleansing swabs80 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).17</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/037</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>18</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 80 micrograms powder and solvent for solution for injection – 12 pens, 12 injection
 needles and 24 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 80 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide80 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>12 pens, 12 injection needles and 24 cleansing swabs80 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).19</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/ 1/00/131/038</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>20</p></section><section><header>minimum particulars to appear on small immediate packaging unitspegintron 80 micrograms powder and solvent for solution for injection
 1.
 name of the medicinal product and route(s) of administration</header><p>pegintron 80 micrograms powder and solvent for injections.c.</p></section><section><header>2.method of administration</header><p>read the package leaflet before use.</p></section><section><header>3.expiry date</header><p>exp</p></section><section><header>4.batch number</header><p>lot</p></section><section><header>5.contents by weight, by volume or by unit</header><p>80 micrograms/0.5 ml21</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 100 micrograms powder and solvent for solution for injection – 1 pen, 1 injection
 needle and 2 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 100 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide100 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>1 pen, 1 injection needle and 2 cleansing swabs100 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).22</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/039</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>23</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 100 micrograms powder and solvent for solution for injection – 4 pens, 4 injection
 needles and 8 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 100 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide100 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>4 pens, 4 injection needles and 8 cleansing swabs100 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).24</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/040</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>25</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 100 micrograms powder and solvent for solution for injection – 6 pens, 6 injection
 needles and 12 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 100 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide100 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>6 pens, 6 injection needles and 12 cleansing swabs100 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).26</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/041</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>27</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 100 micrograms powder and solvent for solution for injection – 12 pens, 12 injection
 needles and 24 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 100 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide100 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>12 pens, 12 injection needles and 24 cleansing swabs100 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).28</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/042</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>29</p></section><section><header>minimum particulars to appear on small immediate packaging unitspegintron 100 micrograms powder and solvent for solution for injection
 1.
 name of the medicinal product and route(s) of administration</header><p>pegintron 100 micrograms powder and solvent for injections.c.</p></section><section><header>2.method of administration</header><p>read the package leaflet before use.</p></section><section><header>3.expiry date</header><p>exp</p></section><section><header>4.batch number</header><p>lot</p></section><section><header>5.contents by weight, by volume or by unit</header><p>100 micrograms/0.5 ml30</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 120 micrograms powder and solvent for solution for injection – 1 pen, 1 injection
 needle and 2 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 120 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide120 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>1 pen, 1 injection needle and 2 cleansing swabs120 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).31</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/043</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>32</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 120 micrograms powder and solvent for solution for injection – 4 pens, 4 injection
 needles and 8 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 120 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide120 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>4 pens, 4 injection needles and 8 cleansing swabs120 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).33</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/044</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>34</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 120 micrograms powder and solvent for solution for injection – 6 pens, 6 injection
 needles and 12 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 120 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide120 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>6 pens, 6 injection needles and 12 cleansing swabs120 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).35</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/045</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>36</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 120 micrograms powder and solvent for solution for injection – 12 pens, 12 injection
 needles and 24 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 120 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide120 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>12 pens, 12 injection needles and 24 cleansing swabs120 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).37</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/046</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>38</p></section><section><header>minimum particulars to appear on small immediate packaging unitspegintron 120 micrograms powder and solvent for solution for injection
 1.
 name of the medicinal product and route(s) of administration</header><p>pegintron 120 micrograms powder and solvent for injections.c.</p></section><section><header>2.method of administration</header><p>read the package leaflet before use.</p></section><section><header>3.expiry date</header><p>exp</p></section><section><header>4.batch number</header><p>lot</p></section><section><header>5.contents by weight, by volume or by unit</header><p>120 micrograms/0.5 ml39</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 150 micrograms powder and solvent for solution for injection – 1 pen, 1 injection
 needle and 2 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 150 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide150 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>1 pen, 1 injection needle and 2 cleansing swabs150 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).40</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/047</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>41</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 150 micrograms powder and solvent for solution for injection – 4 pens, 4 injection
 needles and 8 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 150 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide150 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>4 pens, 4 injection needles and 8 cleansing swabs150 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).42</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/048</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>43</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 150 micrograms powder and solvent for solution for injection – 6 pens, 6 injection
 needles and 12 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 150 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide150 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>6 pens, 6 injection needles and 12 cleansing swabs150 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).44</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/049</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>45</p></section><section><header>particulars to appear on the outer packaging or, where there is noouter packaging, on the immediate packaging
 pegintron 150 micrograms powder and solvent for solution for injection – 12 pens, 12 injection
 needles and 24 cleansing swabs.
 1.
 name of the medicinal product</header><p>pegintron 150 micrograms powder and solvent for solution for injection pre-filled penpeginterferon alfa-2b</p></section><section><header>2.statement of active substance(s)</header><p>one pegintron pre-filled pen contains a sufficient amount of peginterferon alfa-2b to provide150 micrograms in 0.5 ml of peginterferon alfa-2b when reconstituted as recommended.</p></section><section><header>3.list of excipients</header><p>excipients: disodium phosphate, anhydrous; sodium dihydrogen phosphate dihydrate, sucrose andpolysorbate 80. solvent: water for injections.</p></section><section><header>4.pharmaceutical form and contents</header><p>12 pens, 12 injection needles and 24 cleansing swabs150 micrograms/0.5 ml</p></section><section><header>5.method and route(s) of administration</header><p>subcutaneous useread the package leaflet before use.</p></section><section><header>6.special warning that the medicinal product must be stored out
 of the reach and sight of children</header><p>keep out of the reach and sight of children.</p></section><section><header>7.other special warning(s), if necessary
 8.
 expiry date</header><p>exp</p></section><section><header>9.special storage conditions</header><p>store at 2°c – 8°c (in a refrigerator).46</p></section><section><header>10.special precautions for disposal of unused medicinal products
 or waste materials derived from such medicinal products, if
 appropriate</header><p>after injection of the dose, discard the pen in an appropriate container.</p></section><section><header>11.name and address of the marketing authorisation holder</header><p>marketing authorisation holder: sp europe, 73, rue de stalle, b-1180 bruxelles, belgium</p></section><section><header>12.marketing authorisation number(s)</header><p>eu/1/00/131/050</p></section><section><header>13.manufacturer’s batch number</header><p>lot</p></section><section><header>14.general classification for supply</header><p>medicinal product subject to medical prescription.</p></section><section><header>15.instructions on use</header><p>47</p></section><section><header>minimum particulars to appear on small immediate packaging unitspegintron 150 micrograms powder and solvent for solution for injection
 1.
 name of the medicinal product and route(s) of administration</header><p>pegintron 150 micrograms powder and solvent for injections.c.</p></section><section><header>2.method of administration</header><p>read the package leaflet before use.</p></section><section><header>3.expiry date</header><p>exp</p></section><section><header>4.batch number</header><p>lot</p></section><section><header>5.contents by weight, by volume or by unit</header><p>150 micrograms/0.5 ml</p></section></body></xml>